Roivant Sciences Ltd. $ROIV Stock Position Boosted by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. raised its position in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 6,388.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 30,301 shares of the company’s stock after purchasing an additional 29,834 shares during the quarter. Eurizon Capital SGR S.p.A.’s holdings in Roivant Sciences were worth $1,108,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Assenagon Asset Management S.A. boosted its position in shares of Roivant Sciences by 18.2% during the second quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock worth $295,965,000 after buying an additional 1,286,464 shares during the period. Perceptive Advisors LLC raised its position in Roivant Sciences by 3.8% in the 1st quarter. Perceptive Advisors LLC now owns 8,285,461 shares of the company’s stock valued at $229,507,000 after buying an additional 300,000 shares during the last quarter. Pictet Asset Management Holding SA raised its position in Roivant Sciences by 20.3% in the 3rd quarter. Pictet Asset Management Holding SA now owns 4,173,123 shares of the company’s stock valued at $152,597,000 after buying an additional 704,783 shares during the last quarter. Bank of America Corp DE lifted its stake in Roivant Sciences by 8.0% in the 1st quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock valued at $87,638,000 after acquiring an additional 235,493 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Roivant Sciences by 6.1% in the 1st quarter. Janus Henderson Group PLC now owns 3,095,448 shares of the company’s stock valued at $85,790,000 after acquiring an additional 177,339 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. TD Cowen restated a “buy” rating on shares of Roivant Sciences in a research note on Wednesday, October 21st. Stifel Nicolaus started coverage on shares of Roivant Sciences in a research report on Wednesday, September 16th. They set a “buy” rating and a $51.00 price target on the stock. Wolfe Research cut shares of Roivant Sciences from an “outperform” rating to a “peer perform” rating in a research note on Monday, October 12th. UBS Group set a $55.00 price target on shares of Roivant Sciences in a research note on Wednesday, September 9th. Finally, Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Roivant Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $46.82.

Read Our Latest Report on Roivant Sciences

Roivant Sciences Stock Performance

NASDAQ:ROIV opened at $38.71 on Wednesday. Roivant Sciences Ltd. has a 12-month low of $19.96 and a 12-month high of $42.50. The stock’s 50 day moving average price is $37.32 and its two-hundred day moving average price is $32.42.

Insiders Place Their Bets

In related news, Director Melissa Epperly sold 17,750 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $36.10, for a total transaction of $640,775.00. Following the transaction, the director directly owned 14,954 shares of the company’s stock, valued at approximately $539,839.40. The trade was a 54.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Richard Pulik sold 175,000 shares of the company’s stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $41.85, for a total transaction of $7,323,750.00. Following the completion of the transaction, the chief financial officer owned 222,046 shares in the company, valued at approximately $9,292,625.10. This represents a 44.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,672,906 shares of company stock valued at $62,942,248 over the last 90 days. 8.80% of the stock is owned by insiders.

Roivant Sciences Profile

(Free Report)

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.

Featured Articles

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report).

Institutional Ownership by Quarter for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.